Log In
Print
BCIQ
Print
Print this Print this
 

Faslodex, fulvestrant

Also known as: ICI 182,780

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionSelective estrogen receptor down-regulator (SERD)
Molecular Target Estrogen receptor
Mechanism of ActionEstrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsTreat advanced breast cancer in postmenopausal women who had disease progression following aromatase inhibitor (AI) therapy; Treat advanced or metastatic postmenopausal breast cancer; Treat first line advanced breast cancer; Treat hormone receptor-positive metastatic breast cancer; Treat postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer; Treat progressed or recurrent advanced breast cancer in postmenopausal women; Treat treatment-naïve postmenopausal women with hormone receptor-positive metastatic breast cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today